According to a recent survey, wealthy U.S. investors are the most optimistic than they’ve been in months. And of those looking to invest more in the stock market, they have several clear ideas on where they’d like to place thei…
The pharmaceutical industry is ready to fall off a cliff — a “patent cliff.” Over the next few years, some of the world’s most popular and lucrative medicines will go off patent, and generic competition will siphon an estimate…
Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What’s ahead …
Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the pa…
Diabetes is a growing global scourge, but for Big Pharma it’s more of a lifesaver — and many drugmakers are cranking up their research efforts. After all, many existing drugs will soon be losing their patents, and diabetes cou…